|
||
|
American Journal of Medicine
|
|
|
||
|
American Journal of Medicine
|
On the bleeding side, similar to the RE-COVER trial, in RE-MEDY dabigatran was somewhat safer than warfarin with a reduction in any bleeding (Figure 16).[9] The magnitude of the reduction was about 20%, so a worthwhile but not enormous risk reduction in bleeding with dabigatran. Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.
[9] Schulman S, Kearon C, Kakkar AK, et al; for the RE-MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-718.